Zydus Cadila

Indian pharma industry is capable of delivering 100 new drugs by 2047 for global markets backed by enhanced research and development efforts, Zydus Lifesciences Chairman Pankaj R Patel said on Friday. Speaking at an event here, he stressed the need for innovation, capability building, and a focus on societal benefit. "I believe India can deliver 100 new chemical entities or new drugs to the world by 2047 and off course, it will require effort," Patel said while speaking at the SOUL leadership conclave 2025. He termed it a myth that drug discovery requires a billion dollars while emphasising that it is possible with the right approach. Patel also asserted that the people working in an organisation are the most valuable resource and pitched for an environment where people love to work. He also emphasised the evolving nature of leadership, highlighting the importance of humility, vision, and a global perspective. Patel also shared experiences, including the Prime Minister's proactiv

Zydus Lifesciences on Wednesday said the US health regulator has issued ten observations after inspecting its injectable manufacturing plant near Vadodara in Gujarat. The US Food and Drug Administration (USFDA) inspected the facility at Jarod near Vadodara from April 15 to April 23, the drug maker said in a regulatory filing. The inspection closed with ten observations, it added. The company will closely work with the USFDA to address and respond to the observations in an expeditious manner, Zydus Lifesciences said. Shares of the company were trading 2.79 per cent down at Rs 932.80 apiece on the BSE.

The loan was used to fund the acquisition of Zydus Cadila's animal healthcare business in 2021

Unveils 'innovation and care' centric corporate brand identity

Revenue from operations nearly flat at Rs 3,655 crore in reporting quarter

ZyCoV-D is a three-dose vaccine administered intradermally

ZyCoV-D is one of the first plasmid DNA vaccines administered intradermally using a painless needle-free system in three doses.

Cadila Healthcare said group firm Zydus has received final approval from the US health regulator to market its generic version of Vigabatrin tablets

Zydus Cadila's yet to be launched DNA plasmid vaccine ZyCoV-D is expected to add to the vaccine supply

The orphan drug designation provides eligibility for certain development incentives

Zydus Cadila on Monday said it has received approval to commence Phase II clinical study of its upcoming product with patients suffering with Cryopyrin-Associated Periodic Syndromein Australia.

Cariprazine is an atypical antipsychotic medication used for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar disorder.

Training of vaccinators complete on needle free injector system

ZyCov-D, which is the first Covid vaccine to be cleared by India's drug regulator for those aged 12 years and above, will only be administered to adults in the seven states

Meanwhile, Zydus is working with a Korean partner to commercialise ZyCoV-D in South Korea in 2022

The drug will be manufactured at the group's injectables manufacturing facility

The company has received approval from the US Food and Drug Administration (USFDA) for the Nelarabine injection 250 MG/50ML, a generic version of Arranon injection

The ministry has already placed a purchase order with the Ahmedabad-based firm for one crore doses of the vaccine.

ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus

Business Standard brings you the top headlines from today